1. Search Result
Search Result
Results for "

LTB4 receptor

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112741
    SB-209247
    1 Publications Verification

    Leukotriene Receptor Inflammation/Immunology
    SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a Ki of 0.78 nM. SB-209247 blocks LTB4-induced Ca 2+ mobilization with an IC50 of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .
    SB-209247
  • HY-112737

    CGS23131; SKF107324

    Leukotriene Receptor Inflammation/Immunology
    LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [ 3H]LTB4 binding to LTB4 receptor.
    LY223982
  • HY-114641A
    BIIL-260 hydrochloride
    1 Publications Verification

    Leukotriene Receptor Inflammation/Immunology
    BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM .
    BIIL-260 hydrochloride
  • HY-15744
    LY255283
    3 Publications Verification

    Leukotriene Receptor Inflammation/Immunology Cancer
    LY255283 is a LTB4 receptor (BLT2) antagonist, with an IC50 of ~100 nM for [ 3H]LTB4 binding to guinea pig lung membranes .
    LY255283
  • HY-122536

    Leukotriene Receptor Calcium Channel Endogenous Metabolite Inflammation/Immunology
    Ricinelaidic acid, a 12-hydroxy fatty acid,is a leukotriene B4 (LTB4) receptor antagonist with the Ki of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC50=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .
    Ricinelaidic acid
  • HY-115390

    Leukotriene Receptor Cardiovascular Disease Inflammation/Immunology
    14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a Ki value of 27 nM and BLT2 with a Ki value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC50 value of 1 µM .
    14,15-Dehydro Leukotriene B4
  • HY-149083

    Leukotriene Receptor Inflammation/Immunology
    LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM .
    LTB4 antagonist 2
  • HY-117896

    Leukotriene Receptor Inflammation/Immunology
    SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .
    SC-50605
  • HY-114641

    Leukotriene Receptor Inflammation/Immunology
    BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with the Ki value of 1.7 nM .
    BIIL-260
  • HY-100173

    Leukotriene Receptor Inflammation/Immunology
    DW-1350 is a LTB4 receptor antagonist.
    DW-1350
  • HY-113483

    20-COOH LTB4

    Drug Metabolite Leukotriene Receptor Metabolic Disease
    20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis) .
    20-Carboxy-Leukotriene B4
  • HY-13628A

    LY293111 sodium; VML 295 sodium

    Leukotriene Receptor Apoptosis Inflammation/Immunology Cancer
    Etalocib (LY293111) sodium, an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib sodium prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib sodium induces apoptosis .
    Etalocib sodium
  • HY-19304

    BIIL 284

    Leukotriene Receptor Inflammation/Immunology
    Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity .
    Amelubant
  • HY-131651

    LTB4 ethanolamide

    Endogenous Metabolite Leukotriene Receptor Cancer
    Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
    Leukotriene B4 ethanolamide
  • HY-13628
    Etalocib
    2 Publications Verification

    LY293111; VML 295

    Leukotriene Receptor Apoptosis Inflammation/Immunology Cancer
    Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .
    Etalocib
  • HY-U00263

    Leukotriene Receptor Inflammation/Immunology
    LY210073 is a Leukotriene B4 (LTB4) receptor antagonist with an IC50 of 6.2 nM.
    LY210073
  • HY-121621

    Endogenous Metabolite Inflammation/Immunology
    RO5101576 is a potent LTB4 receptor antagonist with activity to inhibit LTB4-induced calcium mobilization and chemotaxis of human neutrophils. RO5101576 significantly attenuated LTB4-induced pulmonary eosinophilia in guinea pigs. RO5101576 inhibited allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy comparable to that of budesonide. RO5101576 had no effect on LPS-induced neutrophilia in guinea pigs and cigarette smoke-induced neutrophilia in mice and rats. RO5101576 performed well in toxicology studies and was well tolerated .
    RO5101576
  • HY-112742

    Leukotriene Receptor Inflammation/Immunology
    CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .
    CP-195543
  • HY-13628R

    Leukotriene Receptor Apoptosis Inflammation/Immunology Cancer
    Etalocib (Standard) is the analytical standard of Etalocib. This product is intended for research and analytical applications. Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .
    Etalocib (Standard)
  • HY-117557

    Leukotriene Receptor Inflammation/Immunology
    LY306669 is a potent and selective leukotriene B4 (LTB4) receptor antagonist that can be used for the research of lung injury .
    LY306669
  • HY-108396

    Ethyl γ-linolenate

    Leukotriene Receptor Inflammation/Immunology
    γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .
    γ-Linolenic acid ethyl ester
  • HY-117706

    Leukotriene Receptor Inflammation/Immunology
    LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM .
    LY 292728
  • HY-117854

    Leukotriene Receptor Inflammation/Immunology
    SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .
    SB 201146
  • HY-W744842

    Ethyl γ-linolenate-d5

    Isotope-Labeled Compounds Leukotriene Receptor Inflammation/Immunology
    γ-Linolenic acid ethyl ester-d5 (Ethyl γ-linolenate-d5) is the deuterium labeled γ-Linolenic acid ethyl ester (HY-108396). γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .
    γ-Linolenic acid ethyl ester-d5
  • HY-19443

    Histamine Receptor Lipoxygenase Inflammation/Immunology
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .
    UCB-35440
  • HY-103360
    J-113863
    3 Publications Verification

    CCR Inflammation/Immunology
    J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .
    J-113863
  • HY-141635

    Endogenous Metabolite Metabolic Disease
    cis-11,14-Eicosadienoic acid methyl ester is a more lipid soluble form of the ω-6 C20-2 fatty acid 11(Z),14(Z)-eicosadienoic acid, a naturally occurring PUFA. 11(Z),14(Z)-Eicosadienoic acid competitively inhibits inosine 5’-monophosphate dehydrogenase (Ki=3.1 μM) and inhibits the binding of LTB4 to its receptor on neutrophils (Ki=3.0 μM). Also, serum levels of eicosadienoic acids negatively correlate with degree of sleep disturbance.3 Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators.
    cis-11,14-Eicosadienoic acid methyl ester

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: